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Background
Asthma is an airway condition and is associated with sig-
nificant morbidity and mortality. The recent updates for
treatment of asthma recommends omalizumab for use as
add-on therapy in adults and children >6 years of age with
inadequately controlled severe persistent allergic asthma.
Omalizumab, a humanized anti-IgE mAb, specifically
binds free IgE. The clinical efficacy of omalizumab has
been well documented in a number of clinical trials. In
these studies omalizumab reduced exacerbations, asthma
symptoms, inhaled corticosteroid and rescue medication
use, and improved quality of life. Similar benefits have
been reported in observational studies in “real-world”
populations of patients. In our clinic we started recently
using omalizumab in patients with severe allergic asthma
using several biomarkers to monitor the asthma severity
like spirometry, exhaled NO (FeNO), asthma control test
(ACT), rhinitis control test. The data are still being col-
lected since most of the patients are within the 16 week
period of evaluation. We want to present one case from
them that has completed the 16 week of treatment.
Case report
A young woman 20 year-old, who suffered a lifetime
history of severe allergic asthma since 3 years of age.
She had several episodes of near fatal asthma the last
one last winter. She is allergic to house dust mites, with
continuous need for the rescue medication, and any
kind of physical activity even walking for long distances
is impossible for her. She couldn’t follow the College
because of the disease. Omalizumab was started on
June 2014, 150 mg every 4 weeks, as add on therapy to
fluticasone-salmeterol 250/50mcg. On week 16 she had
better scores in different biomarkers: ACT: 17 from 15
on day 0, spirometry: FEV1 1.62 (57%) on day 0 to 1.77
(64.5%) on week 16, and FeNO: 16 ppb on day 0 to
14ppb on week 16. The patient is feeling much better;
she had no exacerbation and no need for the rescue
medication. She is able to walk for the first time long
distances without having an asthma attack.
Conclusion
Omalizumab is effective in reducing asthma exacerba-
tions and hospitalisations as an adjunctive therapy to
inhaled steroids. Omalizumab is found to be generally
safe and well-tolerated. Our patient had no side effects.
We observed small changes in the biomarkers but the
therapy looks very promising for the future.
Consent
Written informed consent was obtained from the patient
for publication of this abstract and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
Authors’ details
1University Hospital Center “Mother Teresa”, Tirana, Albania. 2American
Hospital Tirana, Department of Allergology and Clinical Immunology, Tirana,
Albania. 3University Hospital Center “Mother Teresa”, Department of
Allergology and Clinical Immunology, Tirana, Albania. 4Berat Hospital,
Department of Allergology and Clinical Immunology, Berat, Albania.
Published: 23 March 2015
doi:10.1186/2045-7022-5-S2-P18
Cite this article as: Mesonjesi et al.: Omalizumab for severe allergic
asthma: a life changing drug? Clinical and Translational Allergy 2015 5
(Suppl 2):P18.
1University Hospital Center “Mother Teresa”, Tirana, Albania
Full list of author information is available at the end of the article
Mesonjesi et al. Clinical and Translational Allergy 2015, 5(Suppl 2):P18
http://www.ctajournal.com/content/5/S2/P18
© 2015 Mesonjesi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
